EW · Edwards Lifesciences Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 1, 2020; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| TMTT sales | $198.6M | FY2026 Q2 | +47.7% |
|
|
|||
| Adjusted EPS non-GAAP | $0.78 | the second quarter of 2026 | — |
|
|
|||
| Adjusted gross profit margin non-GAAP | 77.6% | the second quarter of 2026 | — |
|
|
|||
| Adjusted operating profit margin non-GAAP | 30% | the second quarter of 2026 | — |
|
|
|||
| Surgical sales | 284M | the second quarter | — |
| TAVR sales | 1.26B | Q2 2026 | — |
|
|
|||
| Surgical global sales from continuing operations | $1.03B | FY2025 | +4.9% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EW
this stock
Edwards Lifesciences Corp
|
$53.31B | +8.2% | +11.5% | 53.2 | 1.7% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 1, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EW | -0.8% | +9.4% | +7.4% | +7.2% | +8.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -0.4% | +6.5% | -4.1% | +4.3% | -4.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.